Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Efficacy and Safety of Ramosetron Injection for Nausea and Vomiting in Colorectal-Cancer Patients Undergoing a Laparoscopic Colectomy: A Randomized, Double-Blind, Comparative Study

Annals of Coloproctology
2018³â 34±Ç 1È£ p.36 ~ p.41
 ( Park Han-Eol ) - Catholic University College of Medicine Department of Surgery

±è¹Î±â ( Kim Min-Ki ) - Catholic University College of Medicine Department of Surgery
°­¿ø°æ ( Kang Won-Kyung ) - Catholic University College of Medicine Department of Surgery

Abstract

Purpose: A laparoscopic colectomy in colorectal-cancer patients is usually associated with a high risk of postoperative nausea and vomiting (PONV). The purpose of this study is to evaluate the efficacy of injection of long-acting 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist for the reduction of PONV in patients with colorectal cancer.

Methods: A total of 48 patients scheduled to undergo a laparoscopic colectomy for colorectal cancer were randomized in a double-blinded fashion. Patients were randomly allocated to 1 of 2 groups and assigned to receive either 0.3 mg of ramosetron intravenously (group A, n = 25) or 2 mL of normal saline (placebo) (group B, n = 22) immediately after the operation. The incidence of PONV, the nausea severity scale score, the visual analogue scale (VAS) score for pain, the total amount of patient-controlled analgesia used, the recovery of bowel function, and morbidities were assessed at 1 hour and at 24, 48, and 72 hours after surgery.

Results: The baseline and the operative characteristics were similar between the groups (P > 0.05). The number of cases without PONV (complete response) was higher for group A (ramosetron) than group B (normal saline): 24 hours after surgery, 92.0% (23 of 25) for group A versus 54.5% (12 of 22) for group B; 48 hours after surgery, 92% (23 of 25) for group A versus 81.8% (18 of 22) for group B (both P < 0.05). No serious adverse events occurred.

Conclusion: Postoperative ramosetron injection is effective for the prevention of PONV after a laparoscopic colectomy in colorectal-cancer patients.

Ű¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í
(Target field)
¿¬±¸´ë»ó
(Population)
¿¬±¸Âü¿©
(Sample size)
´ë»ó¼ºº°
(Gender)
Áúº´Æ¯¼º
(Condition Category)
¿¬±¸È¯°æ
(Setting)
¿¬±¸¼³°è
(Study Design)
¿¬±¸±â°£
(Period)
ÁßÀç¹æ¹ý
(Intervention Type)
ÁßÀç¸íĪ
(Intervention Name)
Ű¿öµå
(Keyword)
À¯È¿¼º°á°ú
(Recomendation)
¿¬±¸ºñÁö¿ø
(Fund Source)
±Ù°Å¼öÁØÆò°¡
(Evidence Hierarchy)
ÃâÆÇ³âµµ
(Year)
Âü¿©ÀúÀÚ¼ö
(Authors)
´ëÇ¥ÀúÀÚ
(1st Authors)
Doi
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå